Prostatype artikelpush

Double Bond Pharmaceutical International AB

Double Bond Pharmaceuticals utvecklar en ny generation av läkemedel inom cancer, infektion och autoimmuna sjukdomar.
BolagEmissionsbeloppTeckningsperiod
RE
Double Bond Pharmaceutical International AB
1 MSEK22 maj 2026
RE
Double Bond Pharmaceutical International AB
1 MSEK16 dec. 2025
FE
Double Bond Pharmaceutical International AB
15,7 MSEK17 juni 2025 - 1 juli 2025
NY
Double Bond Pharmaceutical International AB
-20 feb. 2024 - 20 feb. 2024
NY
Double Bond Pharmaceutical International AB
-5 maj 2023 - 22 maj 2023
NY
Double Bond Pharmaceutical International AB
-6 feb. 2023 - 6 feb. 2023
NY
Double Bond Pharmaceutical International AB
-22 apr. 2022 - 22 apr. 2022
NY
Double Bond Pharmaceutical International AB
-20 sep. 2021 - 20 sep. 2021
NY
Double Bond Pharmaceutical International AB
-30 apr. 2021 - 14 maj 2021
NY
Double Bond Pharmaceutical International AB
-3 mars 2020 - 3 mars 2020
NY
Double Bond Pharmaceutical International AB
-7 feb. 2020 - 26 feb. 2020
NY
Double Bond Pharmaceutical International AB
-3 apr. 2019 - 26 apr. 2019
NY
Double Bond Pharmaceutical International AB
-21 jan. 2019 - 21 jan. 2019
NY
Double Bond Pharmaceutical International AB
-20 dec. 2018 - 20 dec. 2018
NY
Double Bond Pharmaceutical International AB
-24 sep. 2018 - 24 sep. 2018
NY
Double Bond Pharmaceutical International AB
-20 mars 2018 - 5 apr. 2018
NY
Double Bond Pharmaceutical International AB
-7 dec. 2017 - 21 dec. 2017
NY
Double Bond Pharmaceutical International AB
-9 nov. 2017 - 9 nov. 2017
NY
Double Bond Pharmaceutical International AB
-26 apr. 2017 - 26 apr. 2017
NY
Double Bond Pharmaceutical International AB
-22 dec. 2016 - 22 dec. 2016
NY
Double Bond Pharmaceutical International AB
-23 maj 2016 - 7 juni 2016
NY
Double Bond Pharmaceutical International AB
-15 juni 2015 - 30 juni 2015
Double Bond Pharmaceutical International AB

Företagsnamn

Double Bond Pharmaceutical International AB

Organisationsnummer

556991-6082

Address

Virdings allé 32 B 1tr, Uppsala 754 50

Prenumerera på nyhetsbrev

Få de senaste nyheterna om börsnoteringar och nyemissioner direkt i din inkorg.